深度解析医学证据，DeepEvidence为你支撑决策
2026年5月24-27日，第94届欧洲动脉粥样硬化学会年会（EAS 2026）将在希腊雅典盛大举办。作为全球脂质代谢与动脉粥样硬化领域的重要学术盛会，本届大会中Lp(a)相关研究持续升温，从Lp(a)生物学新机制、遗传风险评估、多民族人群研究到级联筛查及创新降Lp(a)疗法临床试验，多项前沿进展集中亮相。Muvalaplin、Evinacumab等新型治疗策略备受关注，Lp(a)检测纳入常规临床管理的实施路径也成为讨论热点。POCKETIN特别梳理EAS 2026大会Lp(a)重点日程，带您抢先聚焦残余心血管风险管理领域的最新突破。
05月24日
Industry Sponsored Session Programme (Not CME-accredited session)
北京时间：18:05
Learn: Unlocking what’s new in Lp(a) biology
学习：揭示Lp(a)生物学的新进展
Pia R. Kamstrup (Denmark)
北京时间：18:20
Prioritize and act now: Lp(a) risk assessment to guide real world care
优先考虑并立即行动：Lp(a)风险评估以指导真实世界临床照护
Erik S. Stroes (Netherlands)
北京时间：18:35
Lp(a): The emerging therapeutic landscape for targeting elevated Lp(a)
Lp(a)：靶向高Lp(a)的新兴治疗格局
Ulrich Laufs (Germany)
05月25日
NLA-EAS Joint Session: Primary prevention of ASCVD
北京时间：15:30
Primary prevention & Lp(a): Updated ESC/EAS Dyslipidemia Guidelines
一级预防与Lp(a)：更新的ESC/EAS血脂异常指南
Borge G. Nordestgaard (Denmark)
Lp(a) in focus: risk stratification, diabetes, and new therapies
北京时间：15:30
The Lp(a) Paradox in Diabetes Mellitus
糖尿病中的Lp(a)悖论
Samia Mora (United States of America)
北京时间：15:50
Which patients await new Lp(a) lowering therapies?
哪些患者在等待新的Lp(a)降低疗法？
Florian Kronenberg (Austria)
北京时间：16:10
LIPOPROTEIN(A) UNDERGOES ENDOTHELIAL TRANSCYTOSIS VIA ACTIVIN RECEPTOR-LIKE KINASE 1: A NOVEL MECHANISM FOR RESIDUAL CARDIOVASCULAR RISK
脂蛋白(a)通过激活素受体样激酶1进行内皮转胞吞作用：残余心血管风险的新机制
Warren L. Lee (Canada)
北京时间：16:20
IMPROVING CARDIOVASCULAR RISK ASSESSMENT WITH GENETICS: VALUE OF AN ASCVD POLYGENIC RISK SCORE AND LP(A) MEASUREMENTS
利用遗传学改善心血管风险评估：ASCVD多基因风险评分和Lp(a)测量的价值
Hannah M. Byrne (Ireland)
北京时间：16:30
LP(A) TESTING AND TREATMENT WITH LP(A)-LOWERING THERAPIES FOR THE PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN HIGH INCOME COUNTRIES: AN EARLY HEALTH TECHNOLOGY ASSESSMENT
高收入国家中用于心血管疾病一级和二级预防的Lp(a)检测及Lp(a)降低疗法的早期卫生技术评估
Zanfina Ademi (Australia)
北京时间：16:40
LIPOPROTEIN(A), ETHNICITY AND CARDIOVASCULAR RISK IN A MULTIETHNIC EUROPEAN COHORT: THE HELIUS STUDY
脂蛋白(a)、种族与多民族欧洲队列中的心血管风险：HELIUS研究
Maxim E. Annink (Netherlands)
北京时间：16:50
ANALYSES OF UNBOUND APOLIPOPROTEIN(A) AND BIOMARKERS OF CARDIOVASCULAR RISK AND KIDNEY DISEASE FOLLOWING MUVALAPLIN TREATMENT: RESULTS FROM A PHASE 2 RANDOMIZED-CONTROLLED TRIAL
Muvalaplin治疗后游离载脂蛋白(a)及心血管风险和肾脏疾病生物标志物的分析：一项2期随机对照试验的结果
Laura F. Michael (United States of America)
SaaG Session: Lipoprotein(a): Genetics, Biology and Clinical Impact
北京时间：18:30
TRANSCRIPTOMIC-BASED CLUSTERING OF HUMAN ATHEROSCLEROTIC PLAQUES IDENTIFIES POTENTIAL UP-REGULATED CALCIUM SIGNALING PATHWAYS FOR ARTERIAL INFLAMMATION BY FDG PET/CT IMAGING IN PATIENTS WITH ELEVATED LIPOPROTEIN(A)
基于转录组学的人类动脉粥样硬化斑块聚类分析，通过FDG PET/CT成像在脂蛋白(a)升高患者中识别出可能上调的钙信号通路与动脉炎症相关
应启迪 宁波市第二医院
北京时间：18:37
CONTRIBUTIONS OF LIPOPROTEIN(A) LEVELS AND AN AORTIC STENOSIS POLYGENIC RISK SCORE TO VALVULAR AND CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH AORTIC STENOSIS
脂蛋白(a)水平和主动脉狭窄多基因风险评分对主动脉狭窄受试者瓣膜及心血管事件的贡献
Arnaud Girard (Canada)
北京时间：18:44
IDENTIFICATION OF ELEVATED LIPOPROTEIN(A) IN FIRST-DEGREE RELATIVES OF PATIENTS WITH ELEVATED LIPOPROTEIN(A): RESULTS FROM A HOSPITAL-BASED CASCADE SCREENING COHORT
在脂蛋白(a)升高患者的一级亲属中识别高脂蛋白(a)：基于医院的级联筛查队列结果
Maxim E. Annink (Netherlands)
北京时间：18:51
ACCURATE ESTIMATION OF LIPOPROTEIN(A) CONCENTRATION VIA ¹H-NMR METABOLOMICS AND ENSEMBLE MACHINE LEARNING
通过¹H-NMR代谢组学和集成机器学习准确估计脂蛋白(a)浓度
Oscar Millet (Spain)
北京时间：18:58
DIRECT LP(A)-C MEASUREMENTS PROVIDE EVIDENCE FOR APO(A) ISOFORM-DEPENDENT CHOLESTEROL COMPOSITION OF LP(A)
直接的Lp(a)-C测量为Lp(a)的载脂蛋白(a)亚型依赖性胆固醇组成提供了证据
Sotirios Tsimikas (United States of America)
北京时间：19:05
LP(A)CCELERATE: CONTEXTUAL ANALYSIS TO INTEGRATE LP(A) TESTING IN ROUTINE CARDIOVASCULAR CARE USING IMPLEMENTATION SCIENCE
Lp(a)加速：利用实施科学将Lp(a)检测整合到常规心血管照护中的背景分析
Manish Saxena (United Kingdom)
北京时间：19:12
DIGIPHYSICAL CASCADE SCREENING FOR LIPOPROTEIN(A) IN PATIENTS WITH CORONARY ARTERY DISEASE: PREDICTORS OF SCREENING PARTICIPATION AND EFFICIENCY
冠状动脉疾病患者中脂蛋白(a)的数字-物理级联筛查：筛查参与和效率的预测因素
Mustafa Suhel (Sweden)
SaaG Session: Vascular Complications of Chronic Kidney Disease and Cardiorenal Disorders
北京时间：18:51
LP(A) UNDER 20 MG/DL PREDICTS HIGH CARDIOVASCULAR RISK IN MEXICANS, INDEPENDENTLY OF THE RS10455872 LPA POLYMORPHISM. THE GEA MEXICAN STUDY RESULTS.
Lp(a)低于20 mg/dL可预测墨西哥人群的高心血管风险，且与rs10455872 LPA多态性无关：GEA墨西哥研究结果
Rosalinda Posadas-Sánchez (Mexico)
SaaG Session: Triglyceride-Rich Lipoproteins and Lipase-Mediated Metabolism
北京时间：19:49
FAMILIAL CHYLOMICRONEMIA SYNDROME IS A NATURAL MODEL OF LP(A) DEFICIENCY
家族性乳糜微粒血症综合征是Lp(a)缺乏的自然模型
Sotirios Tsimikas (United States of America)
北京时间：20:17
LIPOPROTEIN(A) LOWERING AND RISK OF CARDIOVASCULAR DISEASE IN PRIMARY AND SECONDARY PREVENTION
降低脂蛋白(a)与一级和二级预防中心血管疾病风险的关系
Peter E. Thomas (Denmark)
北京时间：20:24
PREVALENCE AND ASSOCIATED DETERMINANTS OF LIPOPROTEIN(A) TESTING IN A CONTEMPORARY COHORT OF US ADULTS FROM THE FAMILY HEART DATABASE®
来自Family Heart Database®的美国成人当代队列中脂蛋白(a)检测的普及率及相关决定因素
Diane MacDougall (United States of America)
SaaG Session: Refining Cardiometabolic Risk Prediction: Lipoproteins, Inflammation and Metabolic Modifiers
北京时间：20:03
RISK FACTOR CONTROL AND IMPLICATIONS FOR EMERGING LP(A)-LOWERING THERAPIES IN INDIVIDUALS WITH ELEVATED LIPOPROTEIN(A) IN GREECE: PRELIMINARY INSIGHTS FROM THE HELP(A) STUDY
危险因素控制及其对希腊高脂蛋白(a)个体新兴Lp(a)降低疗法的启示：HELP(a)研究的初步见解
Marios Kourtidis (Greece)
北京时间：20:10
PROGNOSTIC VALUE OF LIPOPROTEIN(A) FOR ALL-CAUSE AND CARDIOVASCULAR MORTALITY ACROSS THE TRADITIONAL CARDIOVASCULAR RISK CONTINUUM: ANALYSIS FROM NHANES III (1988–1994) WITH FOLLOW-UP TO 2019
脂蛋白(a)在传统心血管风险连续谱中对全因及心血管死亡率的预后价值：NHANES III（1988-1994）分析及随访至2019年
Mustafa H. Al-jarshawi (United Kingdom)
SaaG Session: Endothelial and Smooth Muscle Cell Dynamics in Vascular Disease
北京时间：20:10
INDEPENDENT EFFECTS OF HIGH LIPOPROTEIN(A) LEVELS AND SMALL APOLIPOPROTEIN(A) ISOFORM SIZE ON RISK OF CORONARY ARTERY DISEASE: A MENDELIAN RANDOMIZATION STUDY
高脂蛋白(a)水平与小的载脂蛋白(a)亚型大小对冠状动脉疾病风险的独立效应：一项孟德尔随机化研究
Benjamin Wadstr?m (Denmark)
Late Breaker Abstracts in PCSK9 pharmacology
北京时间：21:39
LIPOPROTEIN(A) LEVELS, RISK OF CARDIOVASCULAR EVENTS AND BENEFIT OF EVOLOCUMAB: FINDINGS FROM THE VESALIUS-CV TRIAL.
脂蛋白(a)水平、心血管事件风险及依洛尤单抗的获益：来自VESALIUS-CV试验的研究结果
Victorien Monguillon (United States of America)
05月26日
SaaG Session: Clinical Management and Therapeutic Optimization in Familial Hypercholesterolemia
北京时间：20:17
EFFECT OF EVINACUMAB ON LP(A) LEVELS IN ADULTS AND ADOLESCENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH): INSIGHTS FROM THE ELIPSE-OPEN LABEL EXTENSION STUDY
Evinacumab对纯合子家族性高胆固醇血症成人和青少年Lp(a)水平的影响：来自ELIPSE开放标签扩展研究的见解
Daniel Gaudet (Canada)
SaaG Session: From Molecular Mechanisms to Cardiovascular Risk Prediction
北京时间：19:56
SEQUENTIAL INCREASES IN LIPOPROTEIN(A) CONCENTRATIONS PREDICT ACUTE CARDIOVASCULAR EVENTS
脂蛋白(a)浓度的依次升高可预测急性心血管事件
Soon Jun Hong (Korea, Republic of)
05月27日
Late Breaker Basic Science Abstracts
北京时间：16:00
PROTEOMIC AND KINETIC ANALYSIS OF INTACT LIPOPROTEIN(A) PARTICLES DEMONSTRATES SLOW APO(A) CLEARANCE AND EXTRACELLULAR VESICLE ASSOCIATION.
完整脂蛋白(a)颗粒的蛋白质组学及动力学分析表明其具有缓慢的载脂蛋白(a)清除及细胞外囊泡结合特性
Gissette Reyes-Soffer (United States of America)